199 related articles for article (PubMed ID: 18715778)
1. Combining biological gene expression signatures in predicting outcome in breast cancer: An alternative to supervised classification.
Nuyten DS; Hastie T; Chi JT; Chang HY; van de Vijver MJ
Eur J Cancer; 2008 Oct; 44(15):2319-29. PubMed ID: 18715778
[TBL] [Abstract][Full Text] [Related]
2. Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice.
Bueno-de-Mesquita JM; Sonke GS; van de Vijver MJ; Linn SC
Ann Oncol; 2011 Sep; 22(9):2021-2030. PubMed ID: 19955335
[TBL] [Abstract][Full Text] [Related]
3. A gene-expression signature as a predictor of survival in breast cancer.
van de Vijver MJ; He YD; van't Veer LJ; Dai H; Hart AA; Voskuil DW; Schreiber GJ; Peterse JL; Roberts C; Marton MJ; Parrish M; Atsma D; Witteveen A; Glas A; Delahaye L; van der Velde T; Bartelink H; Rodenhuis S; Rutgers ET; Friend SH; Bernards R
N Engl J Med; 2002 Dec; 347(25):1999-2009. PubMed ID: 12490681
[TBL] [Abstract][Full Text] [Related]
4. Classification of human breast cancer using gene expression profiling as a component of the survival predictor algorithm.
Glinsky GV; Higashiyama T; Glinskii AB
Clin Cancer Res; 2004 Apr; 10(7):2272-83. PubMed ID: 15073102
[TBL] [Abstract][Full Text] [Related]
5. A novel gene expression signature for bone metastasis in breast carcinomas.
Savci-Heijink CD; Halfwerk H; Koster J; van de Vijver MJ
Breast Cancer Res Treat; 2016 Apr; 156(2):249-59. PubMed ID: 26965286
[TBL] [Abstract][Full Text] [Related]
6. Validation of 70-gene prognosis signature in node-negative breast cancer.
Bueno-de-Mesquita JM; Linn SC; Keijzer R; Wesseling J; Nuyten DS; van Krimpen C; Meijers C; de Graaf PW; Bos MM; Hart AA; Rutgers EJ; Peterse JL; Halfwerk H; de Groot R; Pronk A; Floore AN; Glas AM; Van't Veer LJ; van de Vijver MJ
Breast Cancer Res Treat; 2009 Oct; 117(3):483-95. PubMed ID: 18819002
[TBL] [Abstract][Full Text] [Related]
7. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival.
Chang HY; Nuyten DS; Sneddon JB; Hastie T; Tibshirani R; Sørlie T; Dai H; He YD; van't Veer LJ; Bartelink H; van de Rijn M; Brown PO; van de Vijver MJ
Proc Natl Acad Sci U S A; 2005 Mar; 102(10):3738-43. PubMed ID: 15701700
[TBL] [Abstract][Full Text] [Related]
8. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.
Mook S; Schmidt MK; Viale G; Pruneri G; Eekhout I; Floore A; Glas AM; Bogaerts J; Cardoso F; Piccart-Gebhart MJ; Rutgers ET; Van't Veer LJ;
Breast Cancer Res Treat; 2009 Jul; 116(2):295-302. PubMed ID: 18661261
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of a 92-probe signature in breast cancer.
Akter S; Choi TG; Nguyen MN; Matondo A; Kim JH; Jo YH; Jo A; Shahid M; Jun DY; Yoo JY; Nguyen NN; Seo SW; Ali L; Lee JS; Yoon KS; Choe W; Kang I; Ha J; Kim J; Kim SS
Oncotarget; 2015 Jun; 6(17):15662-80. PubMed ID: 25883221
[TBL] [Abstract][Full Text] [Related]
10. Research-based PAM50 signature and long-term breast cancer survival.
Pu M; Messer K; Davies SR; Vickery TL; Pittman E; Parker BA; Ellis MJ; Flatt SW; Marinac CR; Nelson SH; Mardis ER; Pierce JP; Natarajan L
Breast Cancer Res Treat; 2020 Jan; 179(1):197-206. PubMed ID: 31542876
[TBL] [Abstract][Full Text] [Related]
11. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures.
Fan C; Prat A; Parker JS; Liu Y; Carey LA; Troester MA; Perou CM
BMC Med Genomics; 2011 Jan; 4():3. PubMed ID: 21214954
[TBL] [Abstract][Full Text] [Related]
12. Gene expression variation to predict 10-year survival in lymph-node-negative breast cancer.
Karlsson E; Delle U; Danielsson A; Olsson B; Abel F; Karlsson P; Helou K
BMC Cancer; 2008 Sep; 8():254. PubMed ID: 18778486
[TBL] [Abstract][Full Text] [Related]
13. Genes and functions from breast cancer signatures.
Huang S; Murphy L; Xu W
BMC Cancer; 2018 Apr; 18(1):473. PubMed ID: 29699511
[TBL] [Abstract][Full Text] [Related]
14. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
Bueno-de-Mesquita JM; van Harten WH; Retel VP; van 't Veer LJ; van Dam FS; Karsenberg K; Douma KF; van Tinteren H; Peterse JL; Wesseling J; Wu TS; Atsma D; Rutgers EJ; Brink G; Floore AN; Glas AM; Roumen RM; Bellot FE; van Krimpen C; Rodenhuis S; van de Vijver MJ; Linn SC
Lancet Oncol; 2007 Dec; 8(12):1079-1087. PubMed ID: 18042430
[TBL] [Abstract][Full Text] [Related]
15. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.
Wang Y; Klijn JG; Zhang Y; Sieuwerts AM; Look MP; Yang F; Talantov D; Timmermans M; Meijer-van Gelder ME; Yu J; Jatkoe T; Berns EM; Atkins D; Foekens JA
Lancet; 2005 Feb 19-25; 365(9460):671-9. PubMed ID: 15721472
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling predicts clinical outcome of breast cancer.
van 't Veer LJ; Dai H; van de Vijver MJ; He YD; Hart AA; Mao M; Peterse HL; van der Kooy K; Marton MJ; Witteveen AT; Schreiber GJ; Kerkhoven RM; Roberts C; Linsley PS; Bernards R; Friend SH
Nature; 2002 Jan; 415(6871):530-6. PubMed ID: 11823860
[TBL] [Abstract][Full Text] [Related]
17. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
Bonnefoi H; Potti A; Delorenzi M; Mauriac L; Campone M; Tubiana-Hulin M; Petit T; Rouanet P; Jassem J; Blot E; Becette V; Farmer P; André S; Acharya CR; Mukherjee S; Cameron D; Bergh J; Nevins JR; Iggo RD
Lancet Oncol; 2007 Dec; 8(12):1071-1078. PubMed ID: 18024211
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of transcriptomics based hypoxia signatures in head- and neck squamous cell carcinoma.
Tawk B; Schwager C; Deffaa O; Dyckhoff G; Warta R; Linge A; Krause M; Weichert W; Baumann M; Herold-Mende C; Debus J; Abdollahi A
Radiother Oncol; 2016 Feb; 118(2):350-8. PubMed ID: 26711490
[TBL] [Abstract][Full Text] [Related]
19. Impact of supervised gene signatures of early hypoxia on patient survival.
Seigneuric R; Starmans MH; Fung G; Krishnapuram B; Nuyten DS; van Erk A; Magagnin MG; Rouschop KM; Krishnan S; Rao RB; Evelo CT; Begg AC; Wouters BG; Lambin P
Radiother Oncol; 2007 Jun; 83(3):374-82. PubMed ID: 17532074
[TBL] [Abstract][Full Text] [Related]
20. Fuzzy logic selection as a new reliable tool to identify molecular grade signatures in breast cancer--the INNODIAG study.
Kempowsky-Hamon T; Valle C; Lacroix-Triki M; Hedjazi L; Trouilh L; Lamarre S; Labourdette D; Roger L; Mhamdi L; Dalenc F; Filleron T; Favre G; François JM; Le Lann MV; Anton-Leberre V
BMC Med Genomics; 2015 Feb; 8():3. PubMed ID: 25888889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
